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Abstract
Background
The association of antimicrobial peptides (AMPs) with tuberculosis—diabetes comorbidity
(PTB-DM) is not well understood.
Methods
To study the association of AMPs with PTB-DM, we examined the systemic levels of catheli-
cidin (LL37), human beta defensin– 2 (HBD2), human neutrophil peptides 1–3, (HNP1-3)
and granulysin in individuals with either PTB-DM, PTB, latent TB (LTB) or no TB infection
(NTB).
Results
Circulating levels of cathelicidin and HBD2 were significantly higher and granulysin levels
were significantly lower in PTB-DM compared to PTB, LTB or NTB, while the levels of
HNP1-3 were significantly higher in PTB-DM compared to LTB or NTB individuals. More-
over, the levels of cathelicidin and/or HBD2 were significantly higher in PTB-DM or PTB indi-
viduals with bilateral and cavitary disease and also exhibited a significant positive
relationship with bacterial burden. Cathelidin, HBD2 and HNP1-3 levels exhibited a positive
relationship with HbA1c and/or fasting blood glucose levels. Finally, anti-tuberculosis ther-
apy resulted in significantly diminished levels of cathelicidin, HBD2, granulysin and signifi-
cantly enhanced levels of HNP1-3 and granulysin in PTB-DM and/or PTB individuals.
Conclusion
Therefore, our data demonstrate that PTB-DM is associated with markedly enhanced levels
of AMPs and diminished levels of granulysin.
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Introduction
Pulmonary tuberculosis (PTB), a disease caused by the human pathogen Mycobacterium tuber-
culosis, has recently joined HIV/AIDS as the world’s deadliest infectious disease and affects
more than 10 million people worldwide [1]. Type 2 diabetes mellitus (DM) is rapidly emerging
as one of the world’s most common non-communicable health disease and afflicts over 415
million people worldwide [1]. The confluence of PTB and DM poses a major public health
problem due to the overlap in the geographical distribution of both these diseases, especially in
China and India [2,3]. Moreover, DM is known to promote the risk of acquisition of PTB and
also adversely affect outcomes, including treatment failure, relapse and death [2,4,5]. Both
PTB and PTB-DM now face the additional challenge of emerging drug resistance, including
multi-drug resistance and extensive drug resistance [6]. Therefore, newer strategies to combat
the problem of PTB and PTB-DM are crucially necessary.
Antimicrobial peptides (AMPs), also called host defense peptides, are innate immune effec-
tors that play a vital role in the host defense mechanism against invading pathogens [7]. They
are usually short in length (20–60 amino acid residues), exhibit a cationic and amphipathic
nature and have activity against bacteria, fungi and viruses [8]. It has been shown that AMPs
have high anti-mycobacterial activity but low immunogenicity and are therefore promising
therapeutic agents [9,10]. Few studies have examined the effect of treatment on the systemic
levels of AMPs in PTB or PTB-DM. Among the AMP family, four of the most prominent are
cathelicidin (LL37), human beta defensing– 2 (HBD2), human neutrophil peptide 1–3
(HNP1-3) and granulysin [7]. However, a detailed examination of the association of AMPs
with PTB or PTB-DM and their relationship to disease pathology or bacterial burdens has not
been performed. We therefore postulated that one potential mechanism for increased suscepti-
bility of DM individuals to TB could be a systemic diminution in the levels of AMPs in
PTB-DM individuals.
We performed a detailed examination of the association of the systemic levels of cathelici-
din, HDB2, HNP1-3 and granulysin in PTB-DM and PTB individuals and compared them to
those with latent TB (LTB) or no TB (NTB). In addition, we examined the AMP levels in those
with no TB but DM alone (DM). We demonstrate heightened levels of cathelicidin, HBD2 and
HNP1-3 and diminished levels of granulysin in PTB-DM and PTB. We also demonstrate an
association of cathelicidin and HBD2 with the extent and severity of lung disease and with bac-
terial burdens, as well as correlations of AMPs with glycemic parameters. Finally, we show a
trend towards normalization in the systemic concentrations of these AMPs with standard anti-
tuberculosis treatment in both PTB-DM and PTB individuals.
Materials and methods
Ethics statement
This study was approved by the Ethics Committees of the Prof. M. Viswanathan Diabetes
Research Center and the National Institute for Research in Tuberculosis (NIRT). Written
informed consent was obtained from all participants.
Study population
Plasma samples were collected from 44 individuals with active pulmonary TB and diabetes
mellitus (PTB-DM), 44 individuals with active pulmonary TB and no diabetes (PTB), 30 indi-
viduals with latent TB (LTB), 30 individuals with no TB or diabetes (NTB) and 30 individuals
with diabetes mellitus (DM), recruited in Chennai, India. The diagnosis of PTB was based on
smear and culture positivity for M. tuberculosis. Chest X-rays were used to define cavitary
Antimicrobial peptides in TB-DM
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disease as well as unilateral vs bilateral involvement at enrollment. Smear grades were used to
estimate bacterial burden and classified as 1+, 2+ and 3+. At the time of enrollment, all active
TB cases had no record of prior TB disease or prior anti-TB treatment (ATT). DM was diag-
nosed on the basis of oral glucose tolerance test and/or glycated hemoglobin (HbA1c) levels
(for known diabetics), according to World Health Organization criteria. LTB diagnosis was
based on tuberculin skin test (TST) and Quantiferon TB-Gold in Tube ELISA positivity,
absence of chest radiograph abnormalities or pulmonary symptoms and negative sputum
smear. A positive TST result was defined as an induration of at least 12mm in diameter to min-
imize false positivity due to exposure to environmental mycobacteria. NTB individuals were
asymptomatic with normal chest X-rays, negative TST (induration < 5 mm in diameter) and
Quantiferon ELISA results. No NTB individuals exhibited signs or symptoms of any associated
lung or systemic disease. All individuals were BCG vaccinated, HIV negative had normal body
mass index. The study groups were similar with regard to age and gender; the baseline charac-
teristics of the study participants are shown in Table 1. Standard ATT was administered to
PTB-DM and PTB individuals using the directly observed treatment, short course (DOTS)
strategy. At 6 months following ATT initiation, fresh plasma samples were obtained. All
PTB-DM and PTB individuals were culture negative at the end of ATT.
ELISA
Circulating levels of HBD2 and HNP 1–3 were measured using Mybiosource ELISA kits.
Cathelicidin (LL-37) was measured using Hycult biotech and Granulysin was measured using
Duoset ELISA Development System (R&D Systems) in plasma samples. The lowest detection
limits were as follows: HBD2, 15.6 pg/mL; HNP1-3, 0.625 ng/mL; LL-37, 0.1 ng/mL, Granuly-
sin, 15.625 pg/mL
Statistical analysis
Geometric means (GM) were used for measurements of central tendency. Statistically signifi-
cant differences between the three groups were analyzed using the Kruskal-Wallis test with
Table 1. Demographics of the study groups and biochemical parameters in TB-DM and TB.
Study Demographics PTB-DM PTB LTB NTB DM
No. of subjects recruited 44 44 30 30 30
Gender (Male / Female) 33/11 37/7 18/12 16/14 20/10
Median Age (Range) 50 (34–70) 41 (25–67) 43 (18–65) 36 (18–65) 47 (18–63)
Smear Grade: 0/1+/2+/3+ 0/16/14/14 0/18/16/10 NA NA NA
Culture Results: Negative:0/1+/2+/3+ 0/12/17/15 0/28/12/4 NA NA NA
Tuberculin Skin Test (TST) Not Done Not Done >12mm <12mm Not Done
Interferon gamma release assay Not Done Not Done Positive Negative Not Done
Random Blood Glucose, mg/dL 220 (180–448)* 119 (76–137) 98 (78–113) 96 (60–120) 177 (161–401)
Glycated hemoglobin level, % 10.2 (6.6–15.6)* 5.6 (5.0–5.8) 5.8 (5.01–6.05) 5.7 (4.7–6.1) 7.86 (6.8–11.11)
Serum Triglycerides, mg/dL 108 (33–178)* 74 (39–142) 55 (42–150) 58 (45–144) 99 (41–180)
Total Cholesterol, mg/dL 172 (92–258)* 151 (86–192) 135 (80–198) 131 (78–200) 165 (111–285)
HDL Cholesterol, mg/dL 37 (20–83) 36 (19–69) 30 (19–75) 32 (21–78) 35 (22–78)
LDL Cholesterol, mg/dL 94 (51–165) 83 (49–107) 88 (45–103) 79 (41–98) 98 (55–174)
The values represent the geometric mean (and the range) except for age where the median (and the range) are depicted.
*Represents values that are significantly different in PTB-DM compared to PTB, LTB and NTB.
https://doi.org/10.1371/journal.pone.0184753.t001
Antimicrobial peptides in TB-DM
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Dunn’s correction for multiple comparisons. The Mann-Whitney test was used to compare
antimicrobial peptides concentrations between the individuals with pulmonary TB with uni-
lateral or bilateral lung lesions and cavitary or non-cavitary disease. Linear trend post-test was
used to compare antimicrobial peptides concentrations with sputum smear grades (reflecting
bacterial burdens). Wilcoxon signed rank test was used to compare antimicrobial peptides
concentrations before and after ATT and Holm’s correction for multiple comparisons was
applied. Analyses were performed using Graph-Pad PRISM Version 5.01.
Results
Study population characteristics
The baseline characteristics including demographic and biochemical features of the study pop-
ulation are shown in Table 1. As can be seen, compared to PTB, those with PTB-DM had sig-
nificantly higher levels of random glucose, glycated hemoglobin, serum cholesterol and
triglycerides. No significant differences were observed in age, sex, BMI, smear or culture
grades at baseline between the 2 groups. The demographic and biochemical features of the
other groups in the study, including LTB, NTB and DM are also shown in Table 1.
Heightened circulating levels of cathelicidin, HBD2, HNP1-3 and
diminished levels of granulysin in PTB-DM
To determine the systemic levels of circulating AMPs in PTB-DM and PTB, we measured the
circulating levels of cathelicidin, HBD2, HNP1-3 and granulysin in PTB-DM, PTB, LTB and
NTB individuals (Fig 1). As shown, the circulating levels of cathelicidin (Geometric Mean of
3.9 ng/ml in PTB-DM vs 1.1 ng/ml in PTB, 0.23 ng/ml in LTB and 0.17 ng/ml in NTB), HBD2
(GM of 72.6 pg/ml in PTB-DM vs 28.2 pg/ml in PTB, 13.3 pg/ml in LTB and 3.8 pg/ml in
NTB) and HNP1-3 (GM of 6.3 ng/ml in PTB-DM vs 3.8 ng/ml in LTB and 2.2 ng/ml in NTB)
were significantly higher in PTB-DM compared to PTB and/or LTB and NTB individuals. In
contrast, the circulating levels of granulysin (GM of 38.8 pg/ml in PTB-DM vs 122.9 pg/ml in
PTB, 158.3 pg/ml in LTB and 245.1 pg/ml in NTB) was significantly lower in PTB-DM com-
pared to PTB, LTB and NTB individuals. Similarly, the circulating levels of cathelicidin and
HNP1-3 were significantly higher and those of granulysin significantly lower in PTB compared
to NTB individuals. Thus, PTB-DM is associated with elevated systemic levels of circulating
AMPs, with the exception of granulysin.
Enhanced circulating levels of cathelicidin and HBD2 in PTB-DM
compared to DM
To compare the systemic levels of circulating AMPs between PTB-DM and DM, we measured
the circulating levels of cathelicidin, HBD2, HNP1-3 and granulysin in PTB-DM and DM
alone individuals (Table 2). As shown, the circulating levels of cathelicidin (GM of 3.9 ng/ml
in PTB-DM vs 1.2 ng/ml in DM) and HBD2 (GM of 72.6 pg/ml in PTB-DM vs 5.2 pg/ml in
DM) were significantly higher in PTB-DM compared to DM individuals. Thus, PTB-DM asso-
ciated enhanced levels of AMPs are mainly related to TB disease.
Circulating AMPs are markers of disease severity and bacterial burdens
in PTB-DM
To determine the association between the systemic levels of circulating AMPs and disease
severity in PTB-DM, we measured the circulating levels of cathelicidin, HBD2, HNP1-3 and
granulysin in PTB-DM individuals with unilateral vs bilateral disease and cavitary vs non-
Antimicrobial peptides in TB-DM
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Table 2. Circulating levels of AMPs in PTB-DM and DM individuals.
PTB-DM DM pValue
LL-37 3.94 (1.51–7.82) 1.21 (0.11–4.06) p<0.0001
HBD2 72.63 (13.13–463.01) 5.21 (0.42–109.53) p<0.0001
HNP1-3 2.14 (0.65–16.39) 1.98 (0.25–18.59) p = 0.3487
Granulysin 244.04 (100–818.83) 153.53 (8.12–688.43) p = 0.1469
The values represent thte geometric mean (and the range).
https://doi.org/10.1371/journal.pone.0184753.t002
Fig 1. Elevated circulating levels of AMPs in PTB-DM and PTB individuals. The plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and
granulysin were measured in PTB-DM (n = 44), PTB (n = 44), LTB (n = 30) and NTB (n = 30) individuals. The data are presented as scatter plots with
each circle representing a single individual. P values were calculated using the Kruskal—Wallis test with Dunn’s post—hoc for multiple comparisons.
https://doi.org/10.1371/journal.pone.0184753.g001
Antimicrobial peptides in TB-DM
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cavitary disease. As shown in Fig 2A, the circulating levels of cathelicidin (GM of 4.1 ng/ml in
bilateral vs. 1.6 ng/ml in unilateral disease) and HBD2 (GM of 114.2 pg/ml in bilateral vs. 39.8
pg/ml in unilateral disease) were significantly higher in PTB-DM individuals with bilateral dis-
ease compared to those with unilateral disease. Similarly, as shown in Fig 2B, the circulating
levels of cathelicidin (GM of 4.7 ng/ml in cavitary vs. 2.7 ng/ml in non-cavitary disease) were
significantly higher in PTB-DM individuals with cavitary disease compared to those without.
To determine the association of circulating AMPs and bacterial burdens, we performed a
correlation of the circulating levels of cathelicidin, HBD2, HNP1-3 and granulysin in
PTB-DM individuals with smear grades. As shown in Fig 2C, both cathelicidin and HBD2
exhibited a significant positive correlation with smear grades in PTB-DM individuals, indicat-
ing a positive association of these factors with bacterial burdens. Thus, both disease severity
Fig 2. Elevated circulating levels of cathelicidin and HBD2 in bilateral and cavitary disease in PTB-DM individuals and relationship to
bacterial burden. (A) The plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin were measured in PTB-DM individuals with bilateral vs
unilateral disease. (B) The plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin were measured in PTB-DM individuals with cavitary vs
non-cavitary disease. (C) The relationship between the plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin and smear grades as
estimated by sputum smears was examined in PTB-DM individuals. The data are presented as scatter plots with each circle representing a single
individual. P values were calculated using the Mann-Whitney test or the Linear trend post—test.
https://doi.org/10.1371/journal.pone.0184753.g002
Antimicrobial peptides in TB-DM
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and bacterial burden in PTB-DM is associated with elevated systemic levels of circulating
AMPs.
Circulating AMPs are also markers of disease severity and bacterial
burden in PTB
To determine the association between the systemic levels of circulating AMPs and disease
severity in PTB without DM, we measured the circulating levels of cathelicidin, HBD2, HNP1-
3 and granulysin in PTB individuals with unilateral vs bilateral disease and cavitary vs. non-
cavitary disease. As shown in Fig 3A, the circulating levels of cathelicidin (GM of 2.7 ng/ml in
bilateral vs. 1.3 ng/ml in unilateral disease) and HBD2 (GM of 61.2 pg/ml in bilateral vs. 17.5
Fig 3. Elevated circulating levels of cathelicidin and HBD2 in bilateral and cavitary disease in PTB individuals and relationship to bacterial
burdens. (A) The plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin were measured in PTB individuals with bilateral vs unilateral
disease. (B) The plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin were measured in PTB individuals with cavitary vs non-cavitary
disease. (C) The relationship between the plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin and smear grades as estimated by
sputum smears was examined in PTB individuals. The data are presented as scatter plots with each circle representing a single individual. P values
were calculated using the Mann-Whitney test or the Linear trend post—test.
https://doi.org/10.1371/journal.pone.0184753.g003
Antimicrobial peptides in TB-DM
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pg/ml in unilateral disease) were significantly higher in PTB individuals with bilateral disease
compared to those with unilateral disease. Similarly, as shown in Fig 3B, the circulating levels
of cathelicidin (GM of 3.3 ng/ml in cavitary vs. 1.0 ng/ml in non-cavitary disease) and HBD2
(GM of 161.6 pg/ml in cavitary vs. 31.2 pg/ml in non-cavitary disease) were significantly
higher in PTB individuals with cavitary disease compared to those without.
To determine the association of circulating AMPs and bacterial burdens, we performed a
correlation of the circulating levels of cathelicidin, HBD2, HNP1-3 and granulysin in PTB
individuals with smear grades. As shown in Fig 3C, cathelicidin (but not the other AMPs)
exhibited a significant positive correlation with smear grades in PTB individuals, indicating a
positive association with bacterial burdens. Thus, both disease severity and bacterial burden in
PTB is associated with elevated systemic levels of circulating AMPs.
Circulating cathelicidin and HBD2 exhibit a positive relationship while
granulysin exhibits a negative relationship with HbA1c or fasting blood
glucose levels in PTB
To determine the association between systemic levels of circulating AMPs and glycemic con-
trol in PTB-DM and PTB, we examined the relationship between the circulating levels of
cathelicidin, HBD2, HNP1-3 and granulysin in all PTB individuals with HbA1c levels
(Fig 4A). As shown, the systemic levels of cathelicidin and HBD2 exhibited a significant posi-
tive relationship, while granulysin exhibited a significantly negative relationship with HbA1c
levels in PTB individuals, indicating a significant association of these factors with poor glyce-
mic control. Interestingly, even at the end of anti-TB treatment, the systemic levels of cathelici-
din and HBD2 (and in addition, HNP1-3) exhibited a significantly positive relationship with
HbA1c levels in PTB (Fig 4B). To determine the association between systemic levels of circu-
lating AMPs and glycemic control in PTB, we also examined the relationship between the cir-
culating levels of cathelicidin, HBD2, HNP1-3 and granulysin in all PTB individuals with
fasting blood glucose levels (Fig 4C). As shown, the systemic levels of cathelicidin and HBD2
exhibited a significant positive relationship, while granulysin exhibited a significantly negative
relationship with fasting blood glucose levels in PTB individuals, also indicating a significant
association of these factors with poor glycemic control.
Anti-tuberculosis treatment results in normalizes circulating levels of
AMPs in PTB-DM and PTB
To determine whether the elevated levels of circulating AMPs are directly associated with TB
disease, we determined the levels of these factors in PTB-DM and PTB individuals at baseline
(pre-T) and at the end of 6 months of anti-tuberculosis treatment (post-T). As shown in
Fig 5A, at the end of treatment, the circulating levels of cathelicidin (GM of 2.4 ng/ml at post-
T compared to 3.9 ng/ml at pre-T) and HBD2 (GM of 28.5 pg/ml at post-T compared to 72.6
pg/ml at pre-T) were significantly diminished, while the circulating levels of HNP1-3 (GM of
2.4 ng/ml at post-T compared to 3.9 ng/ml at pre-T) and granulysin (GM of 28.5 pg/ml at
post-T compared to 72.6 pg/ml at pre-T) were significantly increased compared to pre-treat-
ment levels in PTB-DM individuals. Similarly, as shown in Fig 5B, the circulating levels of
cathelicidin (GM of 0.74 ng/ml at post-T compared to 1.1 ng/ml at pre-T) and HBD2 (GM of
20.9 pg/ml at post-T compared to 28.2 pg/ml at pre-T) were significantly decreased, while the
levels of HNP1-3 (GM of 5.4 ng/ml at post-T compared to 7.5 ng/ml at pre-T) were signifi-
cantly increased at post-treatment compared to pre-treatment levels in PTB individuals. Thus,
successful treatment of tuberculosis results in a trend towards normalization of circulating
AMPs in PTB-DM and PTB.
Antimicrobial peptides in TB-DM
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Discussion
AMPs are an important component of the innate immunity to pathogens and are expressed
mainly in phagocytic cells of the immune system, where they exert microbicidal activity
against engulfed pathogens [11]. Many AMPs kill pathogens by disrupting the physical integ-
rity the microbial membrane and/or by translocating across the membrane into the cytoplasm
of bacteria to act on intracellular targets [9]. In addition to a direct antimicrobial effect, AMPs
can regulate the immune response by a variety of mechanisms including chemotaxis, activa-
tion of antigen presenting cells and cytokine induction [12,13]. Recent work has highlighted
the importance of AMPs in host defense against TB [14]. In fact, AMPs have been proposed as
an attractive therapeutic candidate for anti-mycobacterial therapy [10]. However, the role of
Fig 4. Significant correlation between circulating levels of AMPs and glycemic parameters in all PTB individuals. (A) The relationship
between the plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin and HbA1c levels was examined in all PTB individuals at baseline (B)
The relationship between the plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin and HbA1c levels was examined in all PTB
individuals at the end of anti-TB treatment. (C) The relationship between the plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin and
fasting blood glucose (FBG) levels was examined in all PTB individuals at baseline. The data are presented as scatter plots with each circle
representing a single individual. P values were calculated using the Spearman Rank Correlation.
https://doi.org/10.1371/journal.pone.0184753.g004
Antimicrobial peptides in TB-DM
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AMPs in TB-DM comorbidity has been little studied and hence, we sought to examine their
role in this setting.
Cathelicidin is known to elicit a wide range of responses, including both pro- and anti-
inflammatory responses, chemoattractant activity, anti-infective activity in the form of
induced expression of chemokines, pro-angiogenic activity and pro-apoptotic activity [7].
Cathelicidin is considered to be a key molecule for the control of TB. In vitro studies have
clearly demonstrated a pivotal role for cathelicidin in the antimicrobial activity of human mac-
rophages against M. tuberculosis [15]. Thus, in the presence of vitamin D and TLR2 stimula-
tion, macrophages upregulate the expression of cathelicidin, which then exerts anti-
mycobacterial activity [16,17]. Also, vitamin D3 has been shown to induce autophagy in
human monocytes/macrophages via the induction of cathelicidin [18]. In addition,
Fig 5. Altered circulating levels of AMPs at the end of standard anti-tuberculosis therapy in PTB-DM and PTB individuals. (A) The plasma
levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin were measured in PTB-DM individuals at baseline (pre-T) and at 6 months of ATT (post-T).
(B) The plasma levels of cathelicidin (LL37), HBD2, HNP1-3 and granulysin were measured in PTB individuals at baseline (pre-T) and at 6 months of
ATT (post-T). The data are presented as line graphs with each line representing a single individual. P values were calculated using the Wilcoxon
signed rank test.
https://doi.org/10.1371/journal.pone.0184753.g005
Antimicrobial peptides in TB-DM
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cathelicidin expression in alveolar macrophages has also been demonstrated in TB infection
[19]. Finally, the levels of cathelicidin has been to be elevated in the in the serum or bronchoal-
veolar lavage fluid of active TB [20,21].
In agreement with these reports, our study revealed that PTB individuals exhibited signifi-
cantly higher systemic levels of cathelicidin compared to NTB individuals. In addition, our
data also revealed a novel association of cathelicidin levels with the severity of TB disease (as
estimated by the bilateral and cavitary disease) and with estimated bacterial burden. Finally,
our data revealed that systemic levels of cathelicidin are significantly diminished in PTB indi-
viduals following successful ATT. Of additional interest was the find that cathelicidin levels
were significantly elevated in PTB-DM individuals compared to PTB, LTB, NTB and DM
alone individuals; that these levels were positively correlated with severity of disease and
increasing bacterial burdens; that these levels also positively correlated with HbA1c and ran-
dom blood glucose (indicating an association with poor glycemic control) and that these
enhanced levels were significantly diminished following anti—TB treatment. These findings
are in line with a previous report on cathelicidin levels being enhanced in PTB-DM individuals
[22], but differ from a study that showed decreased CAMP gene expression in these individuals
[23].
HBD2 is a human β defensin, which is expressed in epithelial cells and produced by mono-
cytes, macrophages and dendritic cells [24]. The expression of HBD2 is typically induced by
pro-inflammatory cytokines via NF-κB activation [25]. HBD2 is known to have pro-inflamma-
tory effects with the ability to cause upregulation of chemokines, CXCL8 and CCL2 [26].
While HBD2 expression is induced in different cell types by mycobacterial infection [27,28],
very little is known about the role of HBD2 in PTB or PTB-DM. Our data reveal that HBD2
levels are present at significantly enhanced levels in PTB-DM compared to the other groups,
correlates with severity of disease and/or bacterial burdens in PTB and PTB-DM, exhibits a
positive relationship with HbA1c levels and is significantly diminished following TB treatment
in both PTB and PTB-DM. Thus, HBD2 appears to be associated with pathology and bacterial
burdens in PTB-DM and could serve as an important biomarker for both severity of disease
and therapeutic responses following treatment.
HNP1-3 are defensins, produced by neutrophils, monocytes, lymphocytes and natural killer
cells [24]. They were shown to be capable of killing M. tuberculosis in vitro [29] and HNP1-3
levels were found to be elevated in plasma and BAL of active TB patients [30]. Our data reveals
that HNP1-3 levels are present at significantly enhanced levels in PTB-DM and PTB compared
to the other groups, do not correlate with severity of disease and/or bacterial burdens, do not
exhibit a relationship with HbA1c levels and are significantly elevated following TB treatment
in PTB-DM and PTB individuals. Thus, HNP1-3 levels appear to be associated with active
PTB with or without DM, although not directly associated with either severity of disease or
bacterial burden. The differences in the association of HBD2 and HNP1-3 with bacterial bur-
dens might be related to the source of these anti-microbial peptides or their site of production.
Granulysin is a protein found in granules of CD8+ T cells and exhibits antimicrobial activ-
ity against M. tuberculosis in vivo and in vitro [31]. It was first shown to kill extracellular M.
tuberculosis directly by altering the membrane integrity and to decrease the viability of intra-
cellular bacteria in combination with perforin [31]. It was later shown that granulysin levels
are diminished in adult and pediatric TB, a modulation that is reversible with ATT [32,33].
Our data recapitulate those results and show that circulating granulysin levels were indeed
lower in PTB-DM and PTB individuals and that these levels could be enhanced (at least in
PTB-DM) by ATT. Thus, among the AMPs examined in this study, granulysin was the one fac-
tor that was observed to present at diminished levels in active TB. In addition, granulysin levels
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exhibited a negative correlation with HBA1c and fasting blood glucose, indicating that granu-
lysin levels were also influenced by glycemic parameters in PTB-DM.
Our data on AMPs overall suggest that modulation and upregulation of AMPs is a typical
characteristic of TB-DM co-morbidity. Our data also add to the growing list of evidence indi-
cating heightened immune activation in this immune-metabolic nexus. It is therefore impor-
tant to study in the expression of AMPs in primary cells under conditions mimicking DM,
PTB and PTB-DM in the future. AMPs appear to act as reliable and reproducible biomarkers
for therapeutic monitoring of TB-DM disease. Finally, our study reinforces the suggestion that
TB-DM co-morbidity is characterized by systemic immune activation, mostly driven by poorly
controlled hyperglycemia.
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